Skip to main content

Carteolol

ADVERTISEMENT
Identification
Molecular formula
C16H24N2O3
CAS number
51781-06-7
IUPAC name
5-[3-(tert-butylamino)-2-hydroxy-propoxy]-3,4-dihydro-1H-quinolin-2-one
State
State

At room temperature, Carteolol is in a solid state. This property makes it stable under standard conditions and facilitates its handling and storage in pharmaceutical settings.

Melting point (Celsius)
115.00
Melting point (Kelvin)
388.15
Boiling point (Celsius)
545.15
Boiling point (Kelvin)
818.30
General information
Molecular weight
292.38g/mol
Molar mass
292.3820g/mol
Density
1.2848g/cm3
Appearence

Carteolol appears as a white to slightly off-white crystalline powder. It is often provided for pharmaceutical use in this form. The compound is known for its solubility in water and other organic solvents, which aids in its application as an ophthalmic solution.

Comment on solubility

Solubility of 5-[3-(tert-butylamino)-2-hydroxy-propoxy]-3,4-dihydro-1H-quinolin-2-one (C16H24N2O3)

The solubility of a chemical compound can greatly influence its practical applications and biological effectiveness. In the case of 5-[3-(tert-butylamino)-2-hydroxy-propoxy]-3,4-dihydro-1H-quinolin-2-one, we can expect several interesting characteristics:

  • Polar Group Influence: The presence of polar functional groups such as hydroxy (-OH) and amino (-NH2) can enhance the compound's solubility in polar solvents, notably water.
  • Hydrophobic Regions: The tert-butylamino group contributes a hydrophobic character, which may reduce solubility in highly polar solvents but can enhance lipophilicity.
  • Solvent Dependency: Solubility is likely to vary significantly between different solvents. This compound might exhibit good solubility in organic solvents while showing moderate solubility in aqueous solutions.

It's crucial to recognize that factors such as temperature, pH, and the specific solvent used can significantly influence solubility levels. Thus, while the compound appears to contain both hydrophilic and hydrophobic elements, definitive solubility characteristics should be empirically determined.

Overall, the versatility in solubility may offer exciting prospects for its use in various formulations and applications.

Interesting facts

Interesting Facts about 5-[3-(tert-butylamino)-2-hydroxy-propoxy]-3,4-dihydro-1H-quinolin-2-one

This fascinating compound belongs to the class of quinolines, which are known for their diverse pharmacological properties. Here are some intriguing aspects of this compound:

  • Pharmacological Potential: Compounds in the quinoline family have been studied for their potential in treating various diseases, including cancer and infectious diseases.
  • Structure-Activity Relationship: The addition of the tert-butylamino and hydroxy-propoxy groups can significantly influence the biological activity of the compound. This highlights the importance of structural modifications in medicinal chemistry.
  • Research Interest: Studies have shown that modifications in the quinoline scaffold can lead to improved efficacy and reduced toxicity, making this compound a subject of ongoing research.
  • Can Challenge Synthesis: The synthesis of such a complex compound can pose significant challenges due to the functional groups and stereochemistry involved. This adds to the compound's allure within synthetic organic chemistry.

As a student or scientist delving into organic chemistry, understanding the intricacies of quinoline derivatives like this compound can be rewarding, as they often serve as lead compounds for drug development. Each modification can offer new insights into how small changes can lead to vast differences in biological activity.

In essence, the study of 5-[3-(tert-butylamino)-2-hydroxy-propoxy]-3,4-dihydro-1H-quinolin-2-one exemplifies the exciting interplay between structure, activity, and the potential for novel therapies in modern pharmacology. "Sometimes, the beauty of a molecule lies not in its complexity, but in its ability to impact life positively."

Synonyms
CARTEOLOL
51781-06-7
Carteololum
Carteololum [INN-Latin]
5-(3-(tert-Butylamino)-2-hydroxypropoxy)-3,4-dihydroquinolin-2(1H)-one
5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one
Carteolol (INN)
UNII-8NF31401XG
CHEBI:3437
8NF31401XG
CHEMBL839
2(1H)-Quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-
DTXSID3022746
CARTEOLOL [INN]
Carteololum (INN-Latin)
Carteolol [INN:BAN]
5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one
5-(3-(TERT-BUTYLAMINO)-2-HYDROXYPROPOXY)-3,4-DIHYDROCARBOSTYRIL
5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydroquinolin-2-one
carteololo
CARTEOLOL [JAN]
CARTEOLOL [MI]
Prestwick0_000446
Prestwick1_000446
Prestwick2_000446
Prestwick3_000446
CARTEOLOL [VANDF]
CARTEOLOL [WHO-DD]
Oprea1_672850
SCHEMBL24810
BSPBio_000492
SPBio_002431
BPBio1_000542
DTXCID202746
GTPL7142
SCHEMBL23721779
C07AA15
S01ED05
LWAFSWPYPHEXKX-UHFFFAOYSA-N
BCP13007
BDBM50040065
AKOS015918236
DB00521
2(H)-Quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-
5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-3,4-dihydroquinolin-2(1H)-one
NCGC00179541-01
DA-51599
HY-17495
AB00514682
CS-0009237
NS00007545
C06874
D07624
AB00514682_06
EN300-18563029
L000777
Q546434
BRD-A42167015-003-03-7
BRD-A42167015-003-10-2
5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2-ol
5-[3-(tert-Butylamino)-2-hydroxypropoxy]-3,4-dihydro-2(1H)-quinolinone #
5-[3-[(1,1-Dimethylethyl)amino]-2-hydroxypropyl]-3,4-dihydro-2(1H)-quinolinone